RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

gfp, I don't see things as hopeless as you make them out to be. Say the RD data is good. OK, Cortex licenses out CX717 for RD and gains time to test the new AMPAKINES.

Then say again the data is good for the new low and high impacts through Phase I and IIa testing. Remember, the low impacts may be effectual in the treatment of ADHD. And remember also, if the high impacts are proven safe and efficacious in increasing BDNF, Cortex may be sitting on a goal mine here. So Cortex as an entity obviously then has considerable value. And if the company really has nothing much left to do after licensing these compounds out, wouldn't a buyout be the logical endgame then?

Then there's the scenario Jerry related to us. Maybe Cortex merges with a small to mid-cap company with money in its hands, but whose compounds have already been licensed out. This buys Cortex the time it needs perhaps. Or, at some point in time, some BP likes what it sees in Cortex and simply acquires Cortex to add new promising drugs to their pipelines.

Roger Stoll's no fool. I'm sure he'll do the best he can for the company and its shareholders depending on what value Cortex proves to have when we see the results of the upcoming clinical trials.